ReoPro cuts angioplasty complications in half:
This article was originally published in Clinica
Centocor's antithrombotic drug ReoPro cut heart attacks and death six months after angioplasty by 46% in the EPILOG trial (Evaluation of PTCA to Improve Long-Term Outcome by c7E3 GP IIb/IIIa Receptor Blockade). At the same time it reduced the need for emergency revascularisation by 53.7%, said chairman of the Cleveland Clinic's cardiology department Dr Eric Topol. ReoPro inactivates IIb/IIIa binding sites on the surface of blood platelets.